Bill Banning Mitochondrial Replacement Therapy Considered

The US Senate is reviewing a bill that would extend a ban on so-called three-parent embryos.

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

MitochondrionWIKIMEDIA, LADYOFHATSA Senate committee is today (May 19) taking a first look at a bill that would extend a federal ban on mitochondrial replacement therapy (MRT), STAT News reported. The technique involves replacing a woman’s mitochondrial DNA (mtDNA) with genetic material from a third person (or transplanting the nucleus of a fertilized egg into a healthy, third-party cell) to prevent her from passing a severe mitochondrial disease on to her offspring.

Institutions that support MRT-related research are now lobbying Congress to lift this ban.

“We are advocating to remove the [ban] language or to modify it, to allow science around mitochondrial replacement therapy to advance,” said Lynne Boyle, director of federal relations at Oregon Health & Science University, which is home to one of the technique’s pioneers, developmental biologist Shoukhrat Mitalipov.

In December 2015, Congress passed a rider to the fiscal year 2016 budget that banned the use of federal funds for research involving genetically modifying human embryos, which includes MRT. In February, the National Institute of Medicine (IOM) released a report declaring the technique “ethically permissible” when limited to women at risk of transmitting a severe mitochondrial disease. The IOM recommended that MRT should only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies